drugset / Trial / NCT05978908
Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults
RandomizedSequentialQuadruple-blindTreatment
Summary
A Phase I, Randomized, Double-Blind, Placebo-Controlled, First-in-human, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of retro enversio (RT) thymopentin in Healthy Adult Participants and Patients with Amyotrophic Lateral Sclerosis (ALS)
Timeline
- Start
- 2024-02-20
- Primary completion
- 2024-06-03
- Completion
- 2024-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FC-12738 | Peptide | 4 mg | — |
| Subject | FC-12738 | Peptide | 8 mg | — |
| Subject | FC-12738 | Peptide | 16 mg | — |
Indications
No indication recorded.